Source: Annual Congress 2004 - Thoracic oncology
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
P. Blaxill, L. J. Hardie, E. C. Smith, M. M. Muers, C. P. Wild (Leeds, United Kingdom). Loss of heterozygosity detected in plasma DNA of early stage lung cancer patients. Eur Respir J 2004; 24: Suppl. 48, 4107

Member's Comments

No comment yet.

Related content which might interest you: Recognition of aberrant promoter methylation for early diagnosis of lung cancer patients Source: Virtual Congress 2020 – Screening and early lung cancer Year: 2020 Hypermethylation pattern in genomic DNA samples derived from tumor and serum of resected non-small cell lung cancer patients Source: Eur Respir J 2004; 24: Suppl. 48, 674s Year: 2004 Evaluation of promoter hypermethylation in tissue and blood of non-small cell lung cancer patients and association with survival. Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores Year: 2018 Clinical evaluation of the plasma levels of hTERT and EGFR expression as markers for early detection of non-small cell lung cancer Source: Annual Congress 2009 - Basic science and lung cancer Year: 2009 Dysplasia and aberrant methylation profiles in risk and lung cancer patients Source: Eur Respir J 2005; 26: Suppl. 49, 458s Year: 2005 Gender differences in the expression of double strand break genes in early non-small lung cancer (NSCLC) patients Source: Annual Congress 2009 - Basic science and lung cancer Year: 2009 Evaluation of serum tumour markers in the lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 268s Year: 2002 Circulating free DNA, new dynamic marker in nonsmall cell lung cancer patients? Source: Eur Respir J 2015; 46: 1548-1550 Year: 2015 Serum tumor markers in lung cancer patients Source: Annual Congress 2007 - Biology, diagnosis and rare tumours in thoracic malignancies Year: 2007 Characteristics and prognostic relevance of p53 gene mutations in Polish non small cell lung cancer (NSCLC) patients Source: Eur Respir J 2005; 26: Suppl. 49, 92s Year: 2005 Quantification of neutrophil accumulation in early lung cancer Source: International Congress 2018 – Imaging of various diseases with different imaging modalities Year: 2018 DNA methylation is associated with lung function levels in never-smokers Source: International Congress 2017 – Epigenetics of lung function Year: 2017 Concordance of p53 and K-ras mutations in induced sputum and corresponding biopsies of patients with nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 18s Year: 2001 NKX2-1 impacts prognosis in early stage NSCLC not harboring TP53 mutations Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 RARβ2 methylation level in blood for lung cancer assessment Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011 Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status Source: Annual Congress 2011 - Epidemiology of lung cancer and screening Year: 2011 A variant in LKB1 gene can predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management Year: 2018 Early detection of lung cancer: role of biomarkers Source: Eur Respir J 2003; 21: 36S-44S Year: 2003 Polymorphism in GSTM1, GSTT1, p53 and CCR5 genes and lung cancer progression: relation to p53 and Ki-67 protein expression in tumors of non-small cell lung cancer patients Source: Eur Respir J 2006; 28: Suppl. 50, 810s Year: 2006 DNA methylation marker for NSCLC and adjacent normal lung tissue using NotI-MseI methylation chip Source: Eur Respir J 2007; 30: Suppl. 51, 132s Year: 2007